After Illumina CEO’s Fall, Other Executives Are Expected to Take Hard Look at Deals

Francis deSouza resigned from gene-sequencing maker after regulators challenged $7.1 billion deal, triggering proxy fight

Francis deSouza’s resignation from Illumina took effect on Sunday. Photo: Victor J. Blue/Bloomberg News

The abrupt departure of Illumina’s chief executive during a fight with antitrust regulators will give other executives pause before pulling the trigger on deals, antitrust-law specialists said.

Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Continue reading your article with
a WSJ subscription

Subscribe Now

Already a subscriber? Sign In

Sponsored Offers